Abivax S.A. Stock Price, News & Analysis

Abivax (Nasdaq: ABVX) announced that 22 abstracts on obefazimod in inflammatory bowel disease were accepted for presentation at ECCO 2026 (Feb 18–21, 2026) in Stockholm. The program includes 1 oral presentation (Feb 21) reporting the first preclinical evidence of anti-fibrotic activity, 5 digital oral presentations, and 16 posters detailing subgroup analyses, biomarker changes (IL-17A, IL-6), early symptomatic improvements, and an integrated safety summary from the Phase 3 ABTECT induction trials in moderately to severely active ulcerative colitis.

The oral preclinical data address intestinal fibrosis—an unmet need in Crohn’s disease—using human small-intestinal fibroblasts and a TNBS-colitis mouse model; multiple abstracts report pooled and subgroup clinical results and safety findings from ABTECT-1 and ABTECT-2.

Abivax (NASDAQ:ABVX) reported third-quarter 2025 interim results and operational updates on December 15, 2025. Key financials for the nine months ended September 30, 2025 include cash and cash equivalents of EUR 589.7M, a net loss of EUR 254.1M, and an operating loss of EUR 174.4M. The company completed a July 2025 U.S. public offering that generated ~EUR 597.2M net proceeds and drove the larger cash balance and improved net financial position to EUR 543.3M. Abivax highlighted multiple late-breaking presentations of obefazimod ABTECT Phase 3 induction trial data at UEG 2025 and reported a cash runway into Q4 2027.

Abivax (NASDAQ:ABVX) reported patient-reported outcomes from its Phase 3 ABTECT 8-week induction trials of obefazimod in adults with moderate-to-severely active ulcerative colitis on November 3, 2025. Across PRO instruments, the company observed improvements from baseline to Week 8 for both 50mg and 25mg doses.

Key week‑8 results: 37% of patients on 50mg reported no bowel urgency versus 18.1% on placebo; 47.6% on 50mg reported no nocturnal bowel movements versus 24.7% on placebo; 17.1% on 50mg achieved fatigue remission versus 7.7% on placebo. Detailed PRO data and full analyses will be submitted for upcoming medical meetings; a 44-week maintenance readout is expected Q2 2026.

Abivax (NASDAQ:ABVX) announced late‑breaking pooled results from the Phase 3 ABTECT 8‑Week induction trials for obefazimod presented at UEG on October 6, 2025. The PR states that once‑daily 50 mg obefazimod produced clinically meaningful improvements across clinical, endoscopic, and histologic endpoints in populations with and without prior advanced‑therapy inadequate response (AT‑IR). In pooled ABTECT‑1&2 (N=1,272), placebo‑adjusted clinical response differences included +28% (no prior AT‑IR, p<0.0001), +29% (4+ prior AT‑IR, p=0.0242) and +34% (prior JAK inhibitor failure, p=0.0017). The company states obefazimod was well tolerated with no new safety signals. Management hosted a conference call the same day to discuss topline results.

Abivax (NASDAQ:ABVX) announced late-breaking results from the Phase 3 ABTECT 8-week induction trials for obefazimod presented Oct 5, 2025 at UEG. The PR states the pooled 50 mg once-daily dose produced a 16.4% placebo-adjusted clinical remission rate at Week 8 (p<0.0001) and that both ABTECT 1 and 2 met the FDA primary endpoint and all key secondary endpoints at 50 mg.

The trials enrolled 1,272 patients with a refractory population (47% with prior inadequate response to advanced therapy; 21% with prior JAK inhibitor inadequate response). The PR reports no signal for serious, severe, or opportunistic infections or malignancies and provides updated TEAE rates by dose.

Abivax (NASDAQ:ABVX) announced the acceptance of a second late-breaking abstract for its lead drug candidate obefazimod at the 2025 United European Gastroenterology (UEG) Meeting. The presentations will showcase results from the ABTECT Phase 3 induction trials for treating moderately to severely active ulcerative colitis.

Two key presentations are scheduled: The first by Dr. Bruce Sands on October 5, focusing on efficacy and safety results from the 8-week induction trials (ABTECT-1 & 2), and the second by Dr. Silvio Danese on October 6, examining efficacy in patient subsets with and without prior inadequate response to advanced therapies. According to Chief Medical Officer Dr. Fabio Cataldi, the trials demonstrated statistically significant and clinically meaningful activity with an impressive safety profile.

Abivax (NASDAQ: ABVX) announced the upcoming presentation of a late-breaking abstract for obefazimod, their lead drug candidate for treating moderately to severely active ulcerative colitis (UC), at the 2025 United European Gastroenterology (UEG) Meeting in Berlin. The presentation, titled "Efficacy of Obefazimod in ABTECT Phase 3 Induction Trials," will take place on October 6, 2025, at 10:00 AM CET.

The company will host an analyst and investor call at 3 PM CET on the same day and conduct a symposium titled "From Evolution to Revolution: New Mechanisms in Ulcerative Colitis" at 5:30 PM CET. The presentation will focus on 8-week therapy results in patients with and without prior inadequate response to advanced therapies.

Abivax (Euronext: ABVX, Nasdaq: ABVX), a clinical-stage biotechnology company, has been selected to join the CAC Mid 60 and SBF 120 indices following Euronext Paris's annual review. The inclusion will become effective on September 19, 2025, after market close.

The company, which focuses on developing therapeutics for chronic inflammatory diseases, expects this inclusion to enhance its visibility and broaden its investor base, particularly among institutional investors and index-linked funds. CEO Marc de Garidel highlighted this achievement as a validation of the company's strategic vision and execution capabilities.

Abivax (NASDAQ/Euronext: ABVX) reported its H1 2025 financial results, highlighting increased R&D investments and significant capital raising activities. The company recorded an operating loss of EUR 93.7M, up from EUR 80.0M in H1 2024, primarily due to expanded R&D expenses of EUR 77.9M.

Key developments include successful completion of a $747.5M public offering in July 2025 and positive Phase 3 results from ABTECT trials for obefazimod in ulcerative colitis. The company's cash position stood at EUR 60.9M as of June 30, 2025, and with recent financing activities, Abivax expects to fund operations into Q4 2027.

Notable debt conversions occurred post-period, including Heights Capital Management's conversion of EUR 21.9M convertible notes and Kreos Capital's conversion of Tranche A convertible OCABSA.